Clopidogrel Tablet
Product Images NDC 70518-4373

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 70518-4373). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Clopidogrel tablet 75 mg oral dosage form in a quantity of 90 tablets. The label indicates the product is repackaged by RemedyRepack Inc. The tablet is described as round and pink with imprint CL75. Storage instructions note keeping medication out of reach of children and specific temperature ranges (20-25°C with permissible excursions). The label includes NDC 70518-4373-00 and manufacturer info, Ascend Labs, LLC, Montvale, NJ.*

FDA Label Image

Clop02-a (Clop02 A)

A horizontal error bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) at various doses on the active metabolite area under the curve (AUC) of a drug labeled as Plavix. The x-axis represents change relative to Plavix administered alone, ranging from 0.4 to 1.4. Four PPIs are listed: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, each accompanied by a mean value and 90% confidence interval showing their impact on metabolite AUC.*

FDA Label Image

Clop03-a (Clop03 A)

A line graph depicting cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. The y-axis shows cumulative event rate (%) and the x-axis shows months. Two lines compare placebo plus aspirin versus clopidogrel plus aspirin, with placebo showing higher event rates. A note mentions other standard therapies used as appropriate, and the graph includes a p-value of 0.00009.*

FDA Label Image

Clop04-a (Clop04 A)

A forest plot chart showing hazard ratios with 95% confidence intervals for multiple subgroups comparing Clopidogrel versus placebo. The plot includes subgroups by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of Heparin/LMWH, aspirin dose, GPIIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use, with an overall comparison at the bottom. The horizontal axis is labeled as Hazard Ratio (95% CI), ranging approximately from 0.3 to 1.4.*

FDA Label Image

Clop08-a (Clop08 A)

A line graph comparing the cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up between aspirin and clopidogrel treatments. The graph shows two lines, with clopidogrel generally having a lower event rate than aspirin. A p-value of 0.045 is noted on the chart.*

FDA Label Image

Clop_01 (Clop 01)

Chemical structure of clopidogrel bisulfate, showing molecular arrangement including aromatic rings, ester, chlorine atom, and sulfate group (H2SO4).*

FDA Label Image

Clop_05 (Clop 05)

A survival curve chart showing percentage dead before first discharge over days since randomization up to 28 days. It compares deaths in placebo (8.1%) versus clopidogrel tablets (7.5%), indicating a 7% proportional risk reduction with clopidogrel. The chart includes a note that all treated patients received aspirin.*

FDA Label Image

Clop_06 (Clop 06)

A line graph comparing the percentage of patients experiencing death, reinfarction, or stroke before first discharge between those treated with Clopidogrel Tablets and Placebo over 28 days since randomization. The graph shows a lower percentage event rate for Clopidogrel Tablets compared to Placebo, indicating a 9% proportional risk reduction.*

FDA Label Image

Clop_07 (Clop 07)

A forest plot chart showing odds ratios (with 95% confidence intervals) for Clopidogrel Tablets 75 mg versus placebo across various subgroups including gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot illustrates the effect of Clopidogrel Tablets relative to placebo for these subgroups, with no clinical interpretation provided.*

FDA Label Image

Clop_09 (Clop 09)

A hazard ratio forest plot comparing Clopidogrel Tablets and Aspirin across qualifying conditions including Stroke, Myocardial Infarction (MI), and Peripheral Arterial Disease (PAD). The plot shows numerical counts and percentages for each drug group, with horizontal lines and diamonds indicating hazard ratios and confidence intervals along a scale from 0.6 to 1.3.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.